[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:fibroblast-growth-factor-receptor-2":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Fibroblast Growth Factor Receptor 2",7,4,[8,16,23,29,35,43,50],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06439485","Phase I\u002FII Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:16:52.995882Z","2026-05-05T02:43:29.399905Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05727176","Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement",[20],"Phase 2","2026-08-26T02:17:04.346841Z","2026-05-05T02:43:28.866322Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07359820","A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement",[20],"2026-08-26T02:16:54.044282Z","2026-05-05T02:43:28.337919Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06728410","A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement",[20],"2026-08-26T02:19:05.360997Z","2026-05-05T02:43:27.100443Z",{"nct_id":36,"title":37,"phases":38,"status":40,"updated_at":41,"content_modified":42},"NCT06287918","A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations",[39],"Phase 1","NOT_YET_RECRUITING","2026-08-26T02:19:20.945539Z","2026-05-05T02:43:27.603797Z",{"nct_id":44,"title":45,"phases":46,"status":47,"updated_at":48,"content_modified":49},"NCT07393373","Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia",[20],"ENROLLING_BY_INVITATION","2026-08-26T02:18:58.958025Z","2026-06-16T05:54:07.881623Z",{"nct_id":51,"title":52,"phases":53,"status":55,"updated_at":56,"content_modified":57},"NCT05948475","Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma",[54],"Phase 3","ACTIVE_NOT_RECRUITING","2026-08-03T02:32:32.293051Z","2026-05-05T02:43:28.019181Z"]